Beta Bionics 2-Year Revenue Jumps 736% to $103.2 Million
Beta Bionics saw its revenue soar 736% over two years, reaching $103.2 million, driven by the demand for its iLet Bionic Pancreas. The company, which recently went public, is expanding its sales force and developing new products like the Mint patch pump and a bihormonal iLet system. Despite a recent stock dip, Beta Bionics is focused on making its advanced diabetes management technology more accessible through pharmacy reimbursement and continuous innovation.
JPMorgan Chase Boosts Stake in Beta Bionics
JPMorgan Chase has significantly increased its investment in Beta Bionics, a medical device company developing automated insulin delivery solutions for type 1 diabetes. This substantial boost in stake, over 3,200%, indicates growing confidence from Wall Street in Beta Bionics' potential to revolutionize diabetes care with its bionic pancreas technology. The investment firm now holds approximately 0.47% ownership in the Boston-based company.
Segmentation, Major Trends, and Competitive Dynamics in the Insulin Patch Pumps Market
The global insulin patch pumps market is projected to reach $2.55 billion by 2030, growing at a CAGR of 10.2%, driven by advancements in diabetes care technology and increased adoption of closed-loop systems. Key players like Insulet Corporation and Medtronic PLC are innovating with products like the Embecta insulin patch pump, which recently received FDA clearance. The market is segmented by type (reusable, disposable, smart, automated), mode (basal, bolus), and application (Type 1 and Type 2 diabetes), reflecting diverse patient needs and technological progress.
New diabetes report tool flags missed meals, insulin pauses
Beta Bionics has introduced "Bionic Insights" within its Bionic Reports, a new feature designed to help clinicians optimize diabetes care for users of the iLet Bionic Pancreas. This tool organizes patient data into "Areas of Success" and "Areas of Opportunity," highlighting issues like missed meals, insulin pauses, and prolonged hyperglycemia. The aim is to provide actionable guidance, reduce time spent on data interpretation, and facilitate more focused conversations between healthcare providers and patients to improve glucose control.
Beta Bionics Receives 'Moderate Buy' Consensus from Analysts
Beta Bionics (NASDAQ: BBNX), a medical device company specializing in automated insulin delivery, has received a 'Moderate Buy' consensus rating from eleven analysts. The average 12-month price target is $23.20. While the company's iLet Bionic Pancreas system shows promise, analysts' views are mixed due to competitive landscape and regulatory hurdles.
Beta Bionics Introduces Bionic Insights in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
Beta Bionics has launched Bionic Insights, a new feature within its Bionic Reports, designed to enhance diabetes care by providing clinicians with actionable data. This innovation helps healthcare providers make more informed and personalized treatment recommendations for patients using the iLet Bionic Pancreas. Bionic Insights translates complex glucose data into clear guidance, highlighting areas of success and opportunities for improvement to foster better patient-clinician conversations and optimize glucose control.
Beta Bionics to discuss Q1 results April 21 after market close
Beta Bionics (Nasdaq: BBNX) will release its first-quarter 2026 financial results after the market closes on April 21, 2026. The company's management will host a conference call and webcast on the same day at 4:30 PM ET to discuss the financial performance. Investors can access the webcast and replay through the company's investor relations website, with phone access requiring prior registration.
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
Beta Bionics, Inc. (Nasdaq: BBNX) announced it will release its first quarter 2026 financial results after the market closes on Tuesday, April 21, 2026. The company will host a conference call and webcast on the same day at 4:30 pm Eastern Time to discuss its performance. A link to the webcast and dial-in details will be available on the company's investor relations website.
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
Beta Bionics, Inc. announced its plan to release first-quarter 2026 financial results after market close on Tuesday, April 21, 2026. The company will host a conference call and webcast on the same day at 4:30 pm Eastern Time to discuss its performance. The webcast link will be available on the company's investor relations website for live access and future replays.
Beta Bionics (NASDAQ:BBNX) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded Beta Bionics (NASDAQ:BBNX) from a "hold" to a "sell" rating on Sunday, causing its shares to trade down about 6.6%. Despite this downgrade, the stock currently holds an average rating of "Moderate Buy" from analysts with a consensus price target of $23.20. Insider selling has also occurred, with executives selling shares worth over $945,000 in the last 90 days.
BBNX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP, a national securities law firm, is investigating potential claims against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who suffered significant losses. The investigation stems from the company's announcement on January 9, 2026, where it stated an expectation of fewer patient starts in the fourth quarter than analyst estimates, leading to an approximate 37% plunge in its stock. Investors are encouraged to contact Josh Wilson at Faruqi & Faruqi to discuss their legal options regarding potentially misleading statements or undisclosed information by the company.
[SCHEDULE 13G/A] Beta Bionics, Inc. Amended Passive Investment Disclosure | BBNX SEC Filing - Form SCHEDULE 13G/A
The Vanguard Group has filed an amended Schedule 13G/A for Beta Bionics, Inc. (BBNX), reflecting zero beneficial ownership as of March 13, 2026. This change is due to an internal realignment within The Vanguard Group, where certain subsidiaries will now report their beneficial ownership separately, as per SEC Release No. 34-39538. The filing is procedural and clarifies reporting structure rather than indicating a sale or acquisition.
BBNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. (NASDAQ: BBNX) due to misleading statements and/or failure to disclose pertinent information to investors. This investigation follows a significant 37% drop in Beta Bionics' stock on January 9, 2026, after the company announced lower-than-expected patient starts in the fourth quarter. Investors who suffered significant losses in Beta Bionics stock or options are encouraged to contact the firm to discuss their legal rights.
BBNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics (NASDAQ: BBNX) on behalf of investors who suffered significant losses. This investigation follows a 37% drop in the company's stock on January 9, 2026, after Beta Bionics announced expected patient starts in the fourth quarter would be lower than analyst estimates. Investors are encouraged to contact the firm for a discussion of their legal rights.
Lake Street Maintains Beta Bionics(BBNX.US) With Buy Rating, Maintains Target Price $20
Lake Street has reiterated its Buy rating for Beta Bionics (BBNX.US), maintaining a target price of $20. This indicates a continued positive outlook from the firm regarding BBNX.US's stock performance.
Beta Bionics (NASDAQ:BBNX) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen has upgraded Beta Bionics (NASDAQ:BBNX) from a "sell" to a "hold" rating. The company's stock currently holds an average rating of "Moderate Buy" with an average target price of $23.20 from various analysts. Beta Bionics reported stronger-than-expected earnings for its last quarter and recent insider transactions involved selling shares of the company.
ONGOING INVESTIGATION NOTICE: Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP is investigating potential securities claims against Beta Bionics (NASDAQ: BBNX) after the company's shares sharply declined on January 9, 2026. This decline followed Beta Bionics' disclosure of preliminary fourth-quarter 2025 performance metrics that fell short of market expectations, specifically lower-than-anticipated new patient starts for its iLet automated insulin delivery system, causing the stock to drop by 37.04%. The law firm encourages investors who suffered significant losses to contact them for more information regarding the investigation.
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Continues Investigation of Potential Securities Claims Against Bionics (NASDAQ: BBNX)
Faruqi & Faruqi, LLP is continuing its investigation into potential securities claims against Beta Bionics (NASDAQ: BBNX) after the company's shares declined sharply on January 9, 2026. This follows Beta Bionics' disclosure of preliminary fourth-quarter 2025 performance metrics that missed market expectations, specifically regarding lower-than-anticipated new patient starts for its iLet automated insulin delivery system. Investors who suffered significant losses in Beta Bionics stock or options are encouraged to contact Faruqi & Faruqi partner Josh Wilson to discuss their legal rights.
Beta Bionics (BBNX) awards 91,520 stock options to Chief Commercial Officer
Beta Bionics, Inc. (BBNX) has awarded its Chief Commercial Officer, Mark Hopman, 91,520 employee stock options. The options have an exercise price of $12.63 per share and will vest in 36 equal monthly installments beginning March 1, 2026, expiring on February 26, 2036. This grant represents a long-term equity compensation arrangement rather than a direct stock purchase or sale.
Beta Bionics (BBNX) CMO sells 1,025 shares to cover RSU tax withholding
Beta Bionics' Chief Medical Officer, Russell Steven Jon, sold 1,025 shares of Common Stock at an average price of $29.3359 per share on December 2, 2025. This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units. Following the sale, Jon directly holds 178,071 shares of Beta Bionics.
Granahan Investment Management Invests $1.7M in Beta Bionics
Granahan Investment Management LLC has invested $1.7 million in Beta Bionics, acquiring 85,741 shares of the medical device company. This investment highlights confidence in Beta Bionics' iLet Bionic Pancreas system, which aims to revolutionize type 1 diabetes management through automated insulin delivery. Other institutional investors have also adjusted their stakes in the company, signaling broader interest in its potential.
Insider Selling: Beta Bionics (NASDAQ:BBNX) Insider Sells 856 Shares of Stock
Beta Bionics (NASDAQ:BBNX) insider Mark Hopman sold 856 shares of the company's stock on December 2nd, and additional shares on March 2nd and 4th. These sales occurred at prices significantly higher than the stock's current trading value. Despite these insider sales and current unprofitability, institutional investors like Vanguard are increasing their stakes, and analysts maintain a "Moderate Buy" consensus with a target price well above current levels.
Beta Bionics (NASDAQ:BBNX) Insider Sells $30,073.50 in Stock
Beta Bionics (NASDAQ:BBNX) insider Steven Jon Russell sold 1,025 shares of stock worth $30,073.50 on December 2nd, reducing his position by 0.57%. The company recently reported Q4 EPS of -$0.30, beating estimates, but remains unprofitable with significant negative net margin and ROE. Analysts currently have a consensus "Moderate Buy" rating for BBNX with an average price target of $23.20.
Farallon Capital Management LLC Purchases 110,000 Shares of Beta Bionics, Inc. $BBNX
Farallon Capital Management LLC has increased its stake in Beta Bionics, Inc. (NASDAQ:BBNX) by 2.6% in the third quarter, bringing its total ownership to 4,313,920 shares valued at $85,718,000. Other institutional investors have also shown interest in the company. Beta Bionics, a medical device company focused on automated insulin delivery for type 1 diabetes, recently reported quarterly earnings that beat analyst estimates.
Beta Bionics (BBNX) CEO Sean Saint awarded 287,944 stock options at $12.63
Beta Bionics, Inc. CEO Sean Saint was granted 287,944 employee stock options at an exercise price of $12.63 per share, expiring on February 26, 2036. These options will vest in 36 equal monthly installments beginning March 1, 2026, aligning his incentives with the company's long-term performance. This award is a compensation-related acquisition and not an open-market purchase.
Beta Bionics (BBNX) grants 91,520 stock options to CPO
Beta Bionics, Inc. (BBNX) has granted Chief Product Officer Mike Mensinger 91,520 employee stock options at an exercise price of $12.63 per share, expiring on February 26, 2036. These options will vest in 36 equal monthly installments starting March 1, 2026, over a three-year period. This information was disclosed in an amended Form 4/A SEC filing, correcting the number of shares from an earlier filing.
Beta Bionics (BBNX) CMO awarded 91,520 stock options at $12.63 strike
Beta Bionics, Inc. (BBNX) Chief Medical Officer, Russell Steven Jon, was granted 91,520 stock options with an exercise price of $12.63 per share, expiring on February 26, 2036. These options will vest in 36 equal monthly installments starting on March 1, 2026, and represent a compensation award rather than an open-market purchase. This information was reported in an amended SEC Form 4/A filing.
BBNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Launches Investigation into Beta Bionics
Faruqi & Faruqi, LLP has launched an investigation into Beta Bionics (NASDAQ: BBNX) following a sharp decline in its stock price on January 9, 2026. The decline, approximately 37.04%, was triggered by the company's disclosure of preliminary fourth-quarter 2025 performance metrics that missed market expectations, particularly lower-than-anticipated new patient starts for its iLet automated insulin delivery system. The firm encourages investors who suffered significant losses to contact them to discuss legal options.
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who suffered significant losses. This investigation follows Beta Bionics' stock plunge of approximately 37% on January 9, 2026, after the company announced lower-than-estimated patient starts for the fourth quarter. Investors are encouraged to contact attorney James (Josh) Wilson to discuss their legal options.
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. (NASDAQ: BBNX) after the company's stock plunged approximately 37% on January 9, 2026. This drop occurred after Beta Bionics announced an expectation of fewer patient starts in the fourth quarter than analysts had estimated. The law firm is encouraging investors who suffered significant losses to contact them to discuss their legal options.
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who suffered significant losses. This investigation follows a approximately 37% drop in Beta Bionics' stock on January 9, 2026, after the company announced lower-than-expected patient starts in the fourth quarter. The law firm is encouraging affected investors to contact them to discuss their legal options.
[144] Beta Bionics, Inc. SEC Filing
Beta Bionics, Inc. (BBNX) filed a Rule 144 notice proposing the sale of 353 common shares from an equity award, with a transaction date of March 1, 2026. The filing also disclosed prior sales of 2,061 common shares by Mark Hopman on December 4, 2025, for $63,192.28. The company's stock data and recent news are also provided, including financial results and upcoming conference participation.
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Beta Bionics
Faruqi & Faruqi, LLP has launched an investigation into Beta Bionics (NASDAQ: BBNX) following a significant stock drop on January 9, 2026. This probe comes after the company's preliminary fourth-quarter 2025 performance metrics fell short of market expectations, specifically regarding lower-than-anticipated new patient starts for its iLet automated insulin delivery system, causing the stock to fall by over 37%. Investors who suffered losses are encouraged to contact the firm to discuss their legal options.
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP has launched an investigation into Beta Bionics, Inc. following a significant drop in its stock price on January 9, 2026. This decline occurred after the company reported preliminary fourth-quarter 2025 performance metrics that fell short of market expectations, particularly concerning new patient starts for its iLet automated insulin delivery system. The law firm is encouraging investors who suffered losses to contact them to discuss their legal options.
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Beta Bionics
Faruqi & Faruqi, LLP has launched an investigation into Beta Bionics (NASDAQ: BBNX) following a significant stock drop. This comes after the company disclosed preliminary fourth-quarter 2025 performance metrics that fell short of market expectations, specifically concerning new patient starts for its iLet automated insulin delivery system, leading to investor concerns about adoption and revenue growth.
Insider Sell: Mark Hopman Sells Shares of Beta Bionics Inc (BBNX)
Mark Hopman, Chief Commercial Officer of Beta Bionics Inc (BBNX), sold 353 shares of the company on March 4, 2026, reducing his holding to 139,133 shares. This transaction is part of a trend over the past year where Hopman sold 37,290 shares with no purchases, aligning with Beta Bionics' overall insider activity of 0 buys and 34 sells. The sale occurred when shares were trading at $11.57, giving the company a market capitalization of $493.086 million.
Hopman, Beta Bionics CCO, sells $4k in BBNX stock
Beta Bionics CCO Hopman Mark sold 353 shares of BBNX common stock for approximately $4,084 on March 4, 2026, executed under a pre-arranged trading plan. This sale occurred while the stock has declined significantly year-to-date and is considered overvalued by InvestingPro. The company has also recently received mixed analyst assessments regarding its market potential and regulatory status.
First Eagle Investment Management LLC Buys Shares of 233,202 Beta Bionics, Inc. $BBNX
First Eagle Investment Management LLC has acquired 233,202 shares of Beta Bionics, Inc. (NASDAQ: BBNX) for approximately $4.634 million during the third quarter, representing a 0.53% ownership stake. Other institutional investors also increased their holdings in BBNX, while insider sales were noted. The company currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $23.20.
Beta Bionics insider sells $13,151 in stock
Mike Mensinger, an insider at Beta Bionics, sold 1,064 shares of the company's stock for $13,151.04, reducing his stake by 0.56%. While this sale might suggest some uncertainty, his remaining substantial ownership in the company indicates continued belief in its long-term potential. Beta Bionics is a medical device company specializing in automated insulin delivery solutions for type 1 diabetes.
Beta Bionics Insider Sells $10,308 in Stock
Beta Bionics (NASDAQ:BBNX) insider Mark Hopman sold 834 shares of the company's stock on March 2, 2026, totaling $10,308.24. This transaction reduced his direct ownership to 139,486 shares. The sale by a significant shareholder raises questions about the company's outlook and may impact investor sentiment.
[Form 4] Beta Bionics, Inc. Insider Trading Activity
Beta Bionics, Inc.'s CFO, Stephen Feider, reported insider trading activity including the receipt of restricted stock units and stock options, alongside a sale of 1,428 shares to cover tax obligations. These transactions are described as routine equity compensation and tax-management practices. After the sale, Feider directly held 172,729 common shares.
BBNX SEC Filings - Beta Bionics, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to Beta Bionics (BBNX) SEC filings, including annual 10-K reports, quarterly 10-Q statements, and 8-K material event disclosures. It details key financial figures, operational metrics, and clinical data related to their iLet Bionic Pancreas. The article also highlights recent Schedule 13G filings from institutional investors like Morgan Stanley, Sands Capital, and Farallon, indicating significant beneficial ownership in Beta Bionics.
Insider Selling: Beta Bionics (NASDAQ:BBNX) Insider Sells 834 Shares of Stock
Beta Bionics insider Mark Hopman sold 834 shares of BBNX stock for a total of $10,308.24, reducing his stake by 0.59%. This transaction occurred as BBNX shares experienced a 7.6% drop to $11.57 on heavy volume. Despite the insider selling and share drop, analysts maintain a "Moderate Buy" rating with an average target price of $23.20.
Beta Bionics (NASDAQ:BBNX) Insider Steven Jon Russell Sells 1,026 Shares
Beta Bionics (NASDAQ:BBNX) insider Steven Jon Russell sold 1,026 shares of the company's stock on March 2nd at an average price of $12.36, decreasing his stake by 0.57%. The sale totaled $12,681.36, leaving him with 179,096 shares valued at approximately $2.21 million. The stock traded down on Tuesday, hitting $11.57, while the company recently reported earnings that beat estimates but still showed negative margins.
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics (NASDAQ: BBNX) on behalf of investors who suffered significant losses. This investigation follows a approximately 37% drop in Beta Bionics' stock on January 9, 2026, after the company projected fewer patient starts in the fourth quarter than analyst estimates. The law firm encourages affected investors to contact them to discuss their legal options.
FDA warns Beta Bionics on unreported complaints, insulin pump changes
The FDA issued a warning letter to Beta Bionics regarding its automated insulin delivery system, citing unreported complaints of severe high and low blood sugar and unauthorized software modifications. The company is addressing these issues, which include delayed reporting of adverse events, changes related to delayed glucose readings, and hardware problems like leaking insulin cartridges and faulty circuit boards. Beta Bionics has indicated that the warning is not expected to impact its product operations.
Beta Bionics, Inc. ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
Block & Leviton is investigating Beta Bionics, Inc. (Nasdaq: BBNX) for potential securities law violations after its shares fell over 35% in January due to lower-than-expected Q4 2025 patient starts and an FDA warning letter regarding quality system issues. Investors who have lost money are encouraged to contact Block & Leviton to learn about recovering their losses through a potential securities class action lawsuit. The firm is also seeking whistleblowers with non-public information.
Beta Bionics, Inc. ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
Block & Leviton is investigating Beta Bionics, Inc. (Nasdaq: BBNX) for potential securities law violations after its shares fell over 35% in January due to disappointing Q4 2025 results and an FDA warning letter regarding quality system issues. The firm is encouraging investors who have lost money to contact them to learn about recovering losses and offers a whistleblower program for those with non-public information.
BBNX INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who suffered significant losses. The investigation follows a 37% drop in Beta Bionics' stock on January 9, 2026, after the company announced lower-than-expected patient starts for the fourth quarter. Investors are encouraged to contact the law firm to discuss their legal options regarding potentially misleading statements or undisclosed information by the company.
Beta Bionics Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
Beta Bionics Inc has filed for a mixed shelf offering, according to an SEC filing. The size of the offering was not disclosed in the filing. This news was reported by Refinitiv and Reuters.
